Randomized Phase III Trial of Maintenance Bevacizumab With or Without Pemetrexed After First-Line Induction With Bevacizumab, Cisplatin, and Pemetrexed in Advanced Nonsquamous Non–Small-Cell Lung Cancer: AVAPERL (MO22089)

Barlési, Fabrice; Scherpereel, Arnaud; Rittmeyer, Achim; Pazzola, Antonio; Ferrer Tur, Neus; Kim, Joo-Hang; Ahn, Myung‐Ju; G.J.V. Aerts, Joachim; А. Горбунова, В.; Vikström, Anders; K. Wong, Elaine; Ernesto Pérez, Pablo; Mitchell, Lada; J.M. Groen, Harry

doi:10.1200/jco.2012.42.3749

Public

Randomized Phase III Trial of Maintenance Bevacizumab With or Without Pemetrexed After First-Line Induction With Bevacizumab, Cisplatin, and Pemetrexed in Advanced Nonsquamous Non–Small-Cell Lung Cancer: AVAPERL (MO22089)

Published in Journal of Clinical Oncology • Jul 9, 2013

Authors:

Fabrice Barlési

Arnaud Scherpereel

Achim Rittmeyer

Abstract

PURPOSE: Maintenance therapy is associated with improved survival in patients with non-small-cell lung cancer (NSCLC), but few studies have compared active agents in this setting. AVAPERL evaluated the safety and efficacy of bevacizumab with or without pemetrexed as continuation maintenance treatmen...

Subject

Pemetrexed

Bevacizumab

Medicine

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!